MGC018 With or Without MGA012 in Advanced Solid Tumors
Recruiting in Palo Alto (17 mi)
+20 other locations
Age: 18+
Sex: Any
Travel: May be covered
Time Reimbursement: Varies
Trial Phase: Phase 1 & 2
Waitlist Available
Sponsor: MacroGenics
No Placebo Group
Trial Summary
What is the purpose of this trial?This trial is testing a new drug called vobramitamab duocarmazine in patients with advanced solid tumors. It aims to see if the drug is safe and effective in treating these cancers by targeting and killing cancer cells. The study includes patients with several specific types of difficult-to-treat cancers.
Eligibility Criteria
Participant Groups
10Treatment groups
Experimental Treatment
Group I: mCRPC expansionExperimental Treatment1 Intervention
3.0 mg/kg IV every 3 weeks
Group II: TNBC expansionExperimental Treatment1 Intervention
3.0 mg/kg IV every 3 weeks
Group III: SCCHN expansionExperimental Treatment1 Intervention
3.0 mg/kg IV every 3 weeks
Group IV: NSCLC expansionExperimental Treatment1 Intervention
3.0 mg/kg IV every 3 weeks
Group V: Melanoma expansionExperimental Treatment1 Intervention
3.0 mg/kg IV every 3 weeks
Group VI: Cohort 5Experimental Treatment1 Intervention
4.0 mg/kg IV every 3 weeks
Group VII: Cohort 4Experimental Treatment1 Intervention
3.0 mg/kg IV every 3 weeks
Group VIII: Cohort 3Experimental Treatment1 Intervention
2.0 mg/kg IV every 3 weeks
Group IX: Cohort 2Experimental Treatment1 Intervention
1.0 mg/kg IV every 3 weeks
Group X: Cohort 1Experimental Treatment1 Intervention
0.5 mg/kg IV every 3 weeks
Find A Clinic Near You
Research locations nearbySelect from list below to view details:
Inova Schar Cancer InstituteFairfax, VA
Carolina Biooncology InstituteHuntersville, NC
The Johns Hopkins Kimmel Cancer CenterBaltimore, MD
Nebraska Methodist HospitalOmaha, NE
More Trial Locations
Loading ...
Who is running the clinical trial?
MacroGenicsLead Sponsor